Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease

Journal of Neuroscience Research

Volumn 95, Issue 7, 2017, Pages 1360-1372

  Pennisi, Manuela ^a,b   Crupi, Rosalia ^c   Di Paola, Rosanna ^c   Ontario, Maria Laura ^a   Bella, Rita ^a   Calabrese, Edward J ^d   Crea, Roberto ^e   Cuzzocrea, Salvatore ^c   Calabrese, Vittorio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e CreAgri Inc   (United States)

Author keywords

Alzheimer disease; cellular stress response; heme oxygenase; hormesis; hydroxytyrosol

Indexed keywords

CRYOPYRIN; HYDROXYTYROSOL; INFLAMMASOME; KELCH LIKE ECH ASSOCIATED PROTEIN 1; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; AUTACOID;

ALZHEIMER DISEASE; ANTIOXIDANT RESPONSIVE ELEMENT; CELLULAR STRESS RESPONSE; HORMESIS; HUMAN; MOLECULAR PATHOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; HORMESIS; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84998772463     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23986     Document Type: Review

References (149)

1. Abulafia DP, de Rivero Vaccari JP, Lozano JD, Lotocki G, Keane RW, Dietrich WD. 2009. Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab 29:534–544.
2. Adamczak SE, de Rivero Vaccari JP, Dale G, Brand FJ 3rd, Nonner D, Bullock MR, Dahl GP, Dietrich WD, Keane RW. 2014. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J Cereb Blood Flow Metab 34:621–629.
3. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. 2004. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:319–325.
4. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. 2000. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 14:S47–S53.
5. Arunsundar M, Shanmugarajan TS, Ravichandran V. 2015. 3,4-dihydroxyphenylethanol attenuates spatio-cognitive deficits in an Alzheimer's disease mouse model: modulation of the molecular signals in neuronal survival-apoptotic programs. Neurotox Res 27:143–155.
6. Bernini R, Gilardini Montani MS, Merendino N, Romani A, Velotti F. 2015. Hydroxytyrosol-Derived Compounds: A Basis for the Creation of New Pharmacological Agents for Cancer Prevention and Therapy. J Med Chem 58:9089–9107.
7. Berr C, Portet F, Carriere I, Akbaraly TN, Feart C, Gourlet V, Combe N, Barberger-Gateau P, Ritchie K. 2009. Olive oil and cognition: results from the three-city study. Dement Geriatr Cogn Disord 28:357–364.
8. Boche D, Perry VH, Nicoll JA. 2013. Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 39:3–18.
9. Boyden ED, Dietrich WF. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38:240–244.
10. Brieger K, Schiavone S, Miller FJ Jr, Krause KH. 2012. Reactive oxygen species: from health to disease. Swiss Med Wkly 142:w13659.
11. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. 2007. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3:186–191.
12. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN. 2006. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 10:391–397.
13. Calabrese EJ. 2007. Converging concepts: adaptive response, preconditioning, and the Yerkes-Dodson law are manifestations of hormesis. Aging Res Rev 7:8–20.
14. Calabrese EJ. 2008a. Neuroscience and hormesis: overview and general findings. Crit Rev Toxicol 38:249–252.
15. Calabrese EJ. 2008b. Dose-response features of neuroprotective agents: an integrative summary. Crit Rev Toxicol 38:253–348.
16. Calabrese EJ. 2008c. Pharmacological enhancement of neuronal survival. Crit Rev Toxicol 38:349–389.
17. Calabrese EJ. 2013. Hormetic mechanisms. Crit Rev Toxicol 43:580–606.
18. Calabrese EJ. 2016a. Preconditioning is hormesis part I: documentation, dose-response features and mechanistic foundations. Pharmacol Res 110:242–264.
19. Calabrese EJ. 2016b. Preconditioning is hormesis part II: how the conditioning dose mediates protection: dose optimization within temporal and mechanistic frameworks. Pharmacol Res 110:265–275.
20. Calabrese EJ, Baldwin LA. 2002. Defining hormesis. Hum Exper Toxicol 21:91–97.
21. Calabrese EJ, Blain R. 2011. The hormesis database: the occurrence of hermetic dose responses in the toxicological literature. Regul Toxicol Pharmacol 61:73–81.
22. Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L, Cedergreen N, Cherian MG, Chiueh CC, Clarkson TW, et al. 2007. Biological stress response terminology: integrating the concepts of adaptive response and preconditioning stress within a hermetic dose-response framework. Toxicol Appl Pharmacol 222:122–128.
23. Calabrese EJ, Dhawan G, Kapoor R, Iavicoli I, Calabrese V. 2015. What is hormesis and its relevance to healthy aging and longevity? Biogerontology 16:693–707.
24. Calabrese EJ, Dhawan G, Kapoor R, Iavicoli I, Calabrese V. 2016. Hormesis: a fundamental concept with widespread biological and biomedical applications. Gerontology 62:530–535.
25. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Giuffrida Stella AM. 2007a. Nitric oxide in the CNS: neuroprotection versus neurotoxicity. Nature Neurosci 8:766–775.
26. Calabrese V, Mancuso C, Ravagna A, Perluigi M, Cini C, De Marco C, Butterfield DA, Stella AM. 2007b. In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J Neurochem 101:709–717.
27. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA. 2009. Nitric oxide in cell survival: a Janus molecule. Antioxid Redox Signal 11:2717–2739.
28. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP. 2010a. Cellular stress responses, the hormesis paradigm and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13:1763–1811.
29. Calabrese V, Cornelius C, Mancuso C, Lentile R, Stella AM, Butterfield DA. 2010b. Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol Biol 610:285–308.
30. Calabrese V, Cornelius C, Cuzzocrea S, Iavicoli I, Rizzarelli E, Calabrese EJ. 2011. Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. Mol Aspects Med 32:279–304.
31. Calabrese V, Cornelius C, Dinkova-Kostova AT, Iavicoli I, Di Paola R, Koverech A, Cuzzocrea S, Rizzarelli E, Calabrese EJ. 2012. Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity. Biochim Biophys Acta 1822:753–783.
32. Calabrese V, Dattilo S, Petralia A, Parenti R, Pennisi M, Koverech G, Calabrese V, Graziano A, Monte I, Maiolino L, Ferreri T, Calabrese EJ. Analytical approaches to the diagnosis and treatment of aging and aging-related disease: redox status and proteomics. 2015. Free Radic Res 49:511–524.
33. Calabrese V, Giordano J, Signorile A, Laura Ontario M, Castorina S, De Pasquale C, Eckert G, Calabrese EJ. 2016 a. Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. J Neurosci Res 94:1588–1603.
34. Calabrese V, Giordano J, Ruggieri M, Berritta D, Trovato A, Ontario ML, Bianchini R, Calabrese EJ. 2016b. Hormesis, cellular stress response, and redox homeostasis in autism spectrum disorders. J Neurosci Res 94:1488–1498.
35. Casamenti F, Grossi C, Rigacci S, Pantano D, Luccarini I, Stefani M. 2015. Oleuropein aglycone: a possible drug against degenerative conditions. In vivo evidence of its effectiveness against Alzheimer's disease. J Alzheimers Dis 45:679–688.
36. Chakrabarti S, Sinha M, Thakurta IG, Banerjee P, Chattopadhyay M. 2013. Oxidative stress and amyloid beta toxicity in Alzheimer's disease: intervention in a complex relationship by antioxidants. Curr Med Chem 20:4648–4664.
37. Chang J, Yang L, Kouadir M, Peng Y, Zhang S, Shi F, Zhou X, Yin X, Zhao D. 2012. Antibody-mediated inhibition of integrin alpha5beta1 blocks neurotoxic prion peptide PrP106-126-induced activation of BV2 microglia. J Mol Neurosci 48:248–252.
38. Chiurchiù V, Orlacchio A, Maccarrone M. 2016. Is modulation of oxidative stress an answer? The state of the art of redox therapeutic actions in neurodegenerative diseases. Oxid Med Cell Longev 2016:7909380.
39. Christian MS, Sharper VA, Hoberman AM, Seng JE, Fu L, Covell D, Diener RM, Bitler CM, Crea R. 2004. The toxicity profile of hydrolyzed aqueous olive pulp extract. Drug Chem Toxicol 27:309–330.
40. Cobb CA, Cole MP. 2015. Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis 84:4–21.
41. Czeh M, Gressens P, Kaindl AM. 2011. The yin and yang of microglia. Develop Neurosci 33:199–209.
42. Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G, Cotelle P. 2011. Oleuropein and derivatives from olives as Tau aggregation inhibitors. Neurochem Int 58:700–707.
43. Dattilo S, Mancuso C, Koverech G, Di Mauro P, Ontario ML, Petralia CC, Petralia A, Maiolino L, Serra A, Calabrese EJ, et al. 2015. Heat shock proteins and hormesis in the diagnosis and treatment of neurodegenerative diseases. Immun Ageing 12:20.
44. De La Cruz JP, Ruiz-Moreno MI, Guerrero A, López-Villodres JA, Reyes JJ, Espartero JL, Labajos MT, González-Correa JA. 2015. Role of the catechol group in the antioxidant and neuroprotective effects of virgin olive oil components in rat brain. J Nutr Biochem 26:549–555.
45. de la Torre R, Covas MI, Pujadas MA, Fitó M, Farré M. 2006. Is dopamine behind the health benefits of red wine? Eur J Nutr 45:307–310.
46. de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD, Keane RW. 2008. A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci 28:3404–3414.
47. Di Bona D, Scapagnini G, Candore G, Castiglia L, Colonna-Romano G, Duro G, Nuzzo D, Iemolo F, Lio D, Pellicanò M, et al. 2010. Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Curr Pharm Des 16:684–691.
48. Dickinson BC, Chang CJ. 2011. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol 7:504–511.
49. Di Domenico F, Barone E, Perluigi M, Butterfield DA. 2017. The triangle of death in Alzheimer's disease brain: the aberrant cross-talk among energy metabolism, mammalian target of rapamycin signaling, and protein homeostasis revealed by redox proteomics. Antioxid Redox Signal 26:364–387.
50. Dilger RN, Johnson RW. 2008. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukocyte Biol 84:932–939.
51. Dinkova-Kostova AT, Baird L, Holmström KM, Meyer CJ, Abramov AY. 2015. The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics. Biochem Soc Trans 43:602–610.
52. Diomede L, Rigacci S, Romeo M, Stefani M, Salmona M. 2013. Oleuropein aglycone protects transgenic C. elegans strains expressing Aβ42 by reducing plaque load and motor deficit. PLoS One 8:e58893.
53. Dong Y, Benveniste EN. 2001. Immune function of astrocytes. Glia 36:180–190.
54. Féart C, Samieri C, Allès B, Barberger-Gateau P. 2013. Potential benefits of adherence to the Mediterranean diet on cognitive health. Proc Nutr Soc. 72:140–152.
55. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E. 2012. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322:254–262.
56. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509–513.
57. Finkel T. 2011. Signal transduction by reactive oxygen species. J Cell Biol 194:7–15.
58. Franchi L, Munoz-Planillo R, Nunez G. 2012. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 13:325–332.
59. Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O'Connor C, et al. 2013. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PloS One 8:e62143.
60. Furr SR, Chauhan VS, Sterka D Jr, Grdzelishvili V, Marriott I. 2008. Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. J Neurovirol 14:503–513.
61. Gan N, Wu YC, Brunet M, Garrido C, Chung FL, Dai C, Mi L. 2010. Sulforaphane activates heat shock response and enhances proteasome activity through up-regulation of Hsp27. J Biol Chem 285:35528–35536.
62. Giri M, Zhang M, Lü Y. 2016. Genes associated with Alzheimer's disease: an overview and current status. Clin Interv Aging 11:665–681.
63. Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y. 2015. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease. J Neurochem 133:14–25.
64. Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y. 2016. 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochem Res 41:2173–2178.
65. Guo X, Tresserra-Rimbau A, Estruch R, Martínez-González MA, Medina-Remón A, Castañer O, Corella D, Salas-Salvadó J, Lamuela-Raventós RM. 2016. Effects of polyphenol, measured by a biomarker of total polyphenols in urine, on cardiovascular risk factors after a long-term follow-up in the PREDIMED study. Oxid Med Cell Longev doi: 10.1155/2016/2572606.
66. Hafner-Bratkovic I, Bencina M, Fitzgerald KA, Golenbock D, Jerala R. 2012. NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1beta and neuronal toxicity. Cell Mol Life Sci 69:4215–4228.
67. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857–865.
68. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493:674–678.
69. Hoffman HM, Wanderer AA. 2010. Inflammasome and IL-1beta-mediated disorders. Curr Allergy Asthma Rep 10:229–235.
70. Hu X, Liu G, Hou Y, Shi J, Zhu L, Jin D, Peng J, Zhao Y. 2012. Induction of M2-like macrophages in recipient NOD-scid mice by allogeneic donor CD4(+)CD25(+) regulatory T cells. Cell Mol Immunol 9:464–472.
71. Huang WJ, Zhang X, Chen WW. 2016. Role of oxidative stress in Alzheimer's disease. Biomed Rep 4:519–522.
72. Jamilloux Y, Henry T. 2013. The inflammasomes: platforms of innate immunity [in French]. Med Sci 29:975–984.
73. Janczy JR, Ciraci C, Haasken S, Iwakura Y, Olivier AK, Cassel SL, Sutterwala FS. 2014. Immune complexes inhibit IL-1 secretion and inflammasome activation. J Immunol 193:5190–5198.
74. Ji H, Wang Y, Jiang D, Liu G, Xu X, Dai D, Zhou X, Cui W, Li J, Chen Z, et al. 2016. Elevated DRD4 promoter methylation increases the risk of Alzheimer's disease in males. Mol Med Rep 14:2732–2738.
75. Kaushik DK, Gupta M, Kumawat KL, Basu A. 2012. NLRP3 inflammasome: key mediator of neuroinflammation in murine Japanese encephalitis. PloS One 7:e32270.
76. Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, Keane RW. 2014. Pattern recognition receptors and central nervous system repair. Exp Neurol 258:5–16.
77. Kim SB, Bartell SM, Gillen DL. 2016. Inference for the existence of hormetic dose-response relationships in toxicology studies. Biostatistics 17:523–536.
78. Kostomoiri M, Fragkouli A, Sagnou M, Skaltsounis LA, Pelecanou M, Tsilibary EC, Tzinia AK. 2013. Oleuropein, an anti-oxidant polyphenol constituent of olive promotes α-secretase cleavage of the amyloid precursor protein (AβPP). Cell Mol Neurobiol 33:147–154.
79. Ladiwala AR, Mora-Pale M, Lin JC, Bale SS, Fishman ZS, Dordick JS, Tessier PM. 2011. Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β. Chembiochem 12:1749–1758.
80. Lalla R, Donmez G. 2013. The role of sirtuins in Alzheimer's disease. Front Aging Neurosci 5:16.
81. Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, Yang YS, Suh JG, Lee BH, Jin HK, et al. 2012. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation. Neurobiol Aging 33:588–602.
82. Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee HG, Perry G. 2010. Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 10:1201–1208.
83. LeVault KR, Tischkau SA, Brewer GJ. 2015. Circadian disruption reveals a correlation of an oxidative GSH/GSSG redox shift with learning and impaired memory in an Alzheimer's disease mouse model. J Alzheimers Dis 49:301–316.
84. Liu H, Talalay P, Fahey JW. 2016. Biomarker-guided strategy for treatment of autism spectrum disorder (ASD). CNS Neurol Disord Drug Targets 15:602–613.
85. Luccarini I, Pantano D, Nardiello P, Cavone L, Lapucci A, Miceli C, Nediani C, Berti A, Stefani M, Casamenti F. 2016. The polyphenol oleuropein aglycone modulates the PARP1-SIRT1 interplay: an in vitro and in vivo study. J Alzheimers Dis 54:737–750.
86. Lucin KM, Wyss-Coray T. 2009. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64:110–122.
87. Mancuso C, Santangelo R, Calabrese V. 2013. The heme oxygenase/biliverdin reductase system: a potential drug target in Alzheimer's disease. J Biol Regul Homeost Agents. 27:75–87.
88. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241.
89. Masters SL, O'Neill LA. 2011. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol Med 17:276–282.
90. Mattson MP. 2008. Awareness of hormesis will enhance future research in basic and applied neuroscience. Crit Rev Toxicol 38:633–640.
91. Mattson MP. 2014. Challenging oneself intermittently to improve health. Dose Response 12:600–618.
92. Mattson MP. 2015. WHAT DOESN”T KILL YOU…. Sci Am 313:40–45.
93. Mattson MP, Son TG, Camandola S. 2007. Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response 5:174–186.
94. Medina-Remón A, Tresserra-Rimbau A, Pons A, Tur JA, Martorell M, Ros E, Buil-Cosiales P, Sacanella E, Covas MI, Corella D, et al.; PREDIMED Study Investigators. 2015. Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The PREDIMED randomized trial. Nutr Metab Cardiovasc Dis 25:60–77.
95. Meissner F, Molawi K, Zychlinsky A. 2010. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A 107:13046–13050.
96. Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. 2016. Therapies for prevention and treatment of Alzheimer's disease. Biomed Res Int 2016:2589276.
97. Menu P, Vince JE. 2011. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 166:1–15.
98. Minkiewicz J, de Rivero Vaccari JP, Keane RW. 2013. Human astrocytes express a novel NLRP2 inflammasome. Glia 61:1113–1121.
99. Montedoro G, Servili M, Baldioli M, Miniati E. 1992. Simple and hydrolyzable phenolic compounds in virgin olive oil. Their extraction, separation, and quantitative and semiquantitative evaluation by HPLC. J Agric Food Chem 40:1571–1576.
100. Motterlini R, Otterbein LE. 2010. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 9:728–743.
101. Mrak RE, Griffin WS. 2005. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349–354.
102. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417:1–13.
103. Murugaiyah V, Mattson MP. 2015. Neurohormetic phytochemicals: An evolutionary-bioenergetic perspective. Neurochem Int 89:271–280.
104. Paolicelli RC, Bisht K, Tremblay ME. 2014. Fractalkine regulation of microglial physiology and consequences on the brain and behavior. Front Cell Neurosci 8:129.
105. Peng Y, Hou C, Yang Z, Li C, Jia L, Liu J, Tang Y, Shi L, Li Y, Long J, et al. 2016. Hydroxytyrosol mildly improve cognitive function independent of APP processing in APP/PS1 mice. Mol Nutr Food Res 60:2331–2342.
106. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. 2013. Mediterranean diet, stroke, cognitive impairment, and depression: a meta-analysis. Ann Neurol 74:580–591.
107. Puzzo D, Privitera L, Palmeri A. 2012. Hormetic effect of amyloid-beta in synaptic plasticity and memory. Neurobiol Aging 33:1484e15–1484e24.
108. Querfurth HW, LaFerla FM. 2010. Alzheimer's disease. N Engl J Med 362:329–344.
109. Rigacci S. 2015. Olive oil phenols as promising multi-targeting agents against Alzheimer's disease. Adv Exp Med Biol 863:1–20.
110. Rodríguez-Morató J, Xicota L, Fitó M, Farré M, Dierssen M, de la Torre R. 2015. Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases. Molecules 20:4655–4680.
111. Rubartelli A. 2014. DAMP-mediated activation of NLRP3-inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration. Front Immunol 5:99.
112. Rubinsztein DC, Bento CF, Deretic V. 2015. Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med 212:979–990.
113. Safouris A, Tsivgoulis G, Sergentanis TN, Psaltopoulou T. 2015. Mediterranean diet and risk of dementia. Curr Alzheimer Res 12:736–744.
114. Saijo K, Glass CK. 2011. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 11:775–787.
115. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A. 2008. Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell Mol Med 12:2255–2262.
116. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. 2009. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 11:2409–2427.
117. Saresella M, La Rosa F, Piancone F, Zoppis M, Marventano I, Calabrese E, Rainone V, Nemni R, Mancuso R, Clerici M. 2016. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol Neurodegener 11:23.
118. Schaffer S, Müller WE, Eckert GP. 2010. Cytoprotective effects of olive mill wastewater extract and its main constituent hydroxytyrosol in PC12 cells. Pharmacol Res 62:322–327.
119. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. 2016. Alzheimer's disease. Lancet 388:505–517.
120. Schröder H, de la Torre R, Estruch R, Corella D, Martínez-González MA, Salas-Salvadó J, Ros E, Arós F, Flores G, Civit E, Farré M, Fiol M, Vila J, Fernandez-Crehuet J, Ruiz-Gutiérrez V, Lapetra J, Sáez G, Covas MI; PREDIMED Study Investigators 2009. Alcohol consumption is associated with high concentrations of urinary hydroxytyrosol. Am J Clin Nutr 90:1329–1335.
121. Schroder K, Tschopp J. 2010. The inflammasomes. Cell 140:821–832.
122. Schroder K, Zhou R, Tschopp J. 2010. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296–300.
123. Segev-Amzaleg N, Trudler D, Frenkel D. 2013. Preconditioning to mild oxidative stress mediates astroglial neuroprotection in an IL-10-dependent manner. Brain Behav Immun 30:176–185.
124. Shah VB, Huang Y, Keshwara R, Ozment-Skelton T, Williams DL, Keshvara L. 2008. Beta-glucan activates microglia without inducing cytokine production in Dectin-1-dependent manner. J Immunol 180:2777–2785.
125. Sharma R, Sharma A, Chaudhary P, Sahu M, Jaiswal S, Awasthi S, Awasthi YC. 2012. Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane. Free Radic Biol Med 52:2177–2185.
126. Shaw PJ, Lukens JR, Burns S, Chi H, McGargill MA, Kanneganti TD. 2010. Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol 184:4610–4614.
127. Shi F, Yang Y, Kouadir M, Fu Y, Yang L, Zhou X, Yin X, Zhao D. 2013. Inhibition of phagocytosis and lysosomal acidification suppresses neurotoxic prion peptide-induced NALP3 inflammasome activation in BV2 microglia. J Neuroimmunol 260:121–125.
128. Singh K, Zimmerman AW. 2016. Sulforaphane Treatment of Young Men with Autism Spectrum Disorder. CNS Neurol Disord Drug Targets. 15:597–601.
129. Spalletta G, Baldinetti F, Buccione I, Fadda L, Perri R, Scalmana S, Serra L, Caltagirone C. 2004. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. J Neurol 251:688–695.
130. St-Laurent-Thibault C, Arseneault M, Longpré F, Ramassamy C. 2011. Tyrosol and hydroxytyrosol, two main components of olive oil, protect N2a cells against amyloid-β-induced toxicity. Involvement of the NF-κB signaling. Curr Alzheimer Res 8:543–551.
131. Swomley AM, Butterfield DA. 2015. Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics. Arch Toxicol 89:1669–1680.
132. Tan MS, Yu JT, Jiang T, Zhu XC, Tan L. 2013. The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol 48:875–882.
133. Texel SJ, Mattson MP. 2011. Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's disease. Antioxid Redox Signal 14:1519–1534.
134. Tramutola A, Di Domenico F, Barone E, Giorgi A, Di Francesco L, Schinina E, Coccia R, Arena A, Head E, Butterfield DA, et al. 2017. Poly-ubiquitinylation profile in Down syndrome brain before and after the development of Alzheimer neuropathology. Antioxid Redox Signal 26:280–298.
135. Tramutola A, Di Domenico F, Barone E, Perluigi M, Butterfield DA. 2016a. It is all about (u)biquitin: role of altered ubiquitin-proteasome system and UCHL1 in Alzheimer disease. Oxid Med Cell Longev 2016:1–12.
136. Tramutola A, Pupo G, Di Domenico F, Barone E, Arena A, Lanzillotta C, Broekaart D, Blarzino C, Head E, Butterfield DA, et al. 2016b. Activation of p53 in Down syndrome and in the Ts65Dn mouse brain is associated with a pro-apoptotic phenotype. J Alzheimers Dis 52:359–371.
137. Trovato A, Siracusa R, Di Paola R, Scuto M, Ontario ML, Bua O, Di Mauro P, Toscano MA, Petralia CC, Maiolino L, et al. 2016. Redox modulation of cellular stress response and lipoxin A4 expression by Hericium erinaceus in rat brain: relevance to Alzheimer's disease pathogenesis. Immun Ageing doi: 10.1186/s12979-016-0078-8.
138. Valavanidis A, Vlachogianni T, Fiotakis K. 2009. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health 6:445–462.
139. von Bernhardi R, Eugenín J. 2012. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 16:974–1031.
140. Walsh JG, Muruve DA, Power C. 2014. Inflammasomes in the CNS. Nat Rev Neurosci 15:84–97.
141. Wenk GL. 2003. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 64:7–10.
142. Xiang PY, Janc O, Grochowska KM, Kreutz MR, Reymann KG. 2016. Dopamine agonists rescue Aβ-induced LTP impairment by Src-family tyrosine kinases. Neurobiol Aging 40:98–102.
143. Yamamori T, Yasui H, Yamazumi M, Wada Y, Nakamura Y, Nakamura H, Inanami O. 2012. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic Biol Med 53:260–270.
144. Zhang Y, Ahn YH, Benjamin IJ, Honda T, Hicks RJ, Calabrese V, Cole PA, Dinkova-Kostova AT. 2011. HSF1-dependent upregulation of Hsp70 by sulfhydryl-reactive inducers of the KEAP1/NRF2/ARE pathway. Chem Biol 18:1355–1361.
145. Zhang Y, Su TP, Liu B, Zhou Y, Chou KH, Lo CY, Hung CC, Chen WL, Jiang T, Lin CP. 2014. Disrupted thalamo-cortical connectivity in schizophrenia: a morphometric correlation analysis. Schizoph Res 153:129–135.
146. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, Liu L, Shao F. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477:596–600.
147. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. 2008. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement 4:316–323.
148. Zrelli H, Matsuoka M, Kitazaki S, Araki M, Kusunoki M, Zarrouk M, Miyazaki H. 2011. Hydroxytyrosol induces proliferation and cytoprotection against oxidative injury in vascular endothelial cells: role of Nrf2 activation and HO-1 induction. J Agric Food Chem 59:4473–4482.
149. Zuo L, Hemmelgarn BT, Chuang CC, Best TM. 2015. The role of oxidative stress-induced epigenetic alterations in amyloid-β production in Alzheimer's disease. Oxid Med Cell Longev 2015:604658.